Detalhe da pesquisa
1.
Altered NFE2 activity predisposes to leukemic transformation and myelosarcoma with AML-specific aberrations.
Blood
; 133(16): 1766-1777, 2019 04 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-30755419
2.
Concomitant constitutive LNK and NFE2 mutation with loss of sumoylation in a case of hereditary thrombocythemia.
Haematologica
; 106(4): 1158-1162, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32554556
3.
Pharmacological Inhibition of Insulin Growth Factor-1 Receptor (IGF-1R) Alone or in Combination With Ruxolitinib Shows Therapeutic Efficacy in Preclinical Myeloproliferative Neoplasm Models.
Hemasphere
; 5(5): e565, 2021 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-33954282
4.
Phase I dose escalation study of lestaurtinib in patients with myelofibrosis.
Leuk Lymphoma
; 56(9): 2543-51, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25563429